Exact Mass: 354.1775
Exact Mass Matches: 354.1775
Found 157 metabolites which its exact mass value is equals to given mass value 354.1775,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Tephrowatsin A
A hydroxyflavan that is (2S)-flavan substituted by hydroxy group at position 4, methoxy groups at positions 5 and 7 and a prenyl group at position 8 respectively.
3,6-Dimethoxyestra-1,3,5(10),6,8-pentaene-17beta-carboxylic acid methyl ester
Acetylsalvipisone
Acetylsalvipisone is found in alcoholic beverages. Acetylsalvipisone is a constituent of Salvia sclarea (clary sage)
Propofol glucuronide
Propofol glucuronide is a metabolite of propofol. Propofol is a short-acting, intravenously administered hypnotic agent. Its uses include the induction and maintenance of general anesthesia, sedation for mechanically ventilated adults, and procedural sedation. Propofol is also commonly used in veterinary medicine. Propofol is approved for use in more than 50 countries, and generic versions are available. (Wikipedia)
1-dodecanoyl-glycero-3-phosphate
1-dodecanoyl-glycero-3-phosphate is also known as LPA(12:0/0:0) or (2R)-2-Hydroxy-3-(phosphonooxy)propyl laurate. 1-dodecanoyl-glycero-3-phosphate is considered to be practically insoluble (in water) and acidic. 1-dodecanoyl-glycero-3-phosphate is a glycerophosphate lipid molecule
LysoPA(i-12:0/0:0)
LysoPA(i-12:0/0:0) is a lysophosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. Fatty acids containing 16 and 18 carbons are the most common. LysoPA(i-12:0/0:0), in particular, consists of one chain of isododecanoic acid at the C-1 position. Lysophosphatidic acid is the simplest possible glycerophospholipid. It is the biosynthetic precursor of phosphatidic acid. Although it is present at very low levels only in animal tissues, it is extremely important biologically, influencing many biochemical processes.
3-(4-(2-Dimethylamino-1-methylethoxy)phenyl)-1H-pyrazolo(3,4-b)pyridine-1-acetic acid
Ethyl (2S,3S)-3-[[(2S)-1-[[(2S)-1-hydroxypent-4-yn-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylate
Bronica
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D011448 - Prostaglandin Antagonists D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents R - Respiratory system > R03 - Drugs for obstructive airway diseases D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents Seratrodast (AA 2414), an orally active antiasthmatic agent, is a thromboxane A2 receptor (TP) antagonist and ferroptosis inhibitor. Seratrodast reduces lipid ROS production, modulates the systemic xc-/GSH/GPX4 axis, and inhibits JNK phosphorylation and p53 expression. Seratrodast exhibits anti-asthmatic and anti-epileptic activity[1][2][3].
7-(2,5-Dihydroxy-3,4,6-trimethylphenyl)-7-phenylhept-6-enoic acid
3beta-acetoxyl-8beta,10beta-dihydroxy-6beta-methoxyeremophilenolide
6beta-acetoxy-7beta-hydroxy-1beta-methoxy-1alpha,8alpha-oxido-10beta,11betaH-eremophilan-12,8-olide
3alpha-propionyloxy-5beta-(4-hydroxytigloyloxy)-7-hydroxycarvotacetone|3alpha-propionyloxy-5beta-<4-hydroxytigloyloxy>-7-hydroxycarvotacetone
4-O-beta-D-Glucopyranoside-4-Hydroxy-3-(3-methyl-2-butenyl)benzenemethanol
1-O-beta-Glucopyranoside-2-Methyl-6-(3-methyl-2-butenyl)-1,4-benzenediol,9CI
(1beta,5alpha,7beta,8beta)-8-(acetyloxy)-5-hydroperoxy-1-hydroxycostic acid methyl ester|methyl rel-(2R,3R,4aS,5R,8aR)-3-(acetyloxy)decahydro-8a-hydroperoxy-5-hydroxy-4a-methyl-a,8-bis(methylene)naphthalene-2-acetate
Isobutyric acid 2-methoxy-4-[3-(isobutyryloxy)-1,2-dihydroxypropyl]phenyl ester
4alpha,10beta-dihydroxy-3alpha-methoxy-8alpha-acetoxy-11betaH-guai-1-en-12,6alpha-olide
2,3-Dimethoxy-7-methyl-9,10-methylenedioxy-5,6,13,13a-tetrahydro-8H-dibenzo[a,g]quinolizine-7-ium
2,2,4-Trimethylpentane-1,3-diyl dibenzoate
CONFIDENCE standard compound; INTERNAL_ID 1387; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10463; ORIGINAL_PRECURSOR_SCAN_NO 10461 CONFIDENCE standard compound; INTERNAL_ID 1387; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10565; ORIGINAL_PRECURSOR_SCAN_NO 10560 CONFIDENCE standard compound; INTERNAL_ID 1387; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10586; ORIGINAL_PRECURSOR_SCAN_NO 10581
Acetylsalvipisone
1,5-DIPHENYL-4-ETHYL-3-(4-METHOXYPHENYL)-1H-PYRAZOLE
6-[3-[[tert-butyl(dimethyl)silyl]oxymethyl]pyrrolidin-1-yl]-2-fluoropyridine-3-carboxylic acid
2-(4-Tert-Butylphenyl)-5-(4-Biphenyl)-1,3,4-Oxadiazole
N-(hydroxymethyl)prop-2-enamide,2-methylidenebutanoic acid,methyl 2-methylprop-2-enoate,prop-2-enenitrile
BENZYL 4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDIN-3-YLCARBAMATE
N-(6-METHOXY-PYRIDIN-3-YL)-4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-BENZAMIDE
N-Benzyl-2-nitro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
1,3-DIPHENYL-4-ETHYL-5-(4-METHOXYPHENYL)-1H-PYRAZOLE
Iclaprim
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01E - Sulfonamides and trimethoprim > J01EA - Trimethoprim and derivatives C471 - Enzyme Inhibitor > C2153 - Dihydrofolate Reductase Inhibitor D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists C254 - Anti-Infective Agent > C258 - Antibiotic
4,4-bis-(2,3-Epoxypropoxy)-3,3,5,5-tetramethylbiphenyl
1-hydroxy-6,6,9-trimethyl-3-pentylbenzo[c]chromene-2-carboxylic acid
Benzyl (5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)carbamate
TERT-BUTYL 4-AMINOSPIRO[CHROMAN-2,4-PIPERIDINE]-1-CARBOXYLATE HYDROCHLORIDE
BENZYL (5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDIN-3-YL)CARBAMATE
5-[[(2R)-2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl]methyl]pyrimidine-2,4-diamine
1-[2-[[3-(2-Cyanophenoxy)-2-hydroxypropyl]amino]ethyl]-3-phenylurea
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists
3-(3,5-Dimethyl-1-pyrazolyl)-6-[4-(4-fluorophenyl)-1-piperazinyl]-1,2,4,5-tetrazine
4-(9H-fluoren-9-yl)-N-(4-pyridinylmethylene)-1-piperazinamine
Seratrodast
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D011448 - Prostaglandin Antagonists D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents R - Respiratory system > R03 - Drugs for obstructive airway diseases D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents Seratrodast (AA 2414), an orally active antiasthmatic agent, is a thromboxane A2 receptor (TP) antagonist and ferroptosis inhibitor. Seratrodast reduces lipid ROS production, modulates the systemic xc-/GSH/GPX4 axis, and inhibits JNK phosphorylation and p53 expression. Seratrodast exhibits anti-asthmatic and anti-epileptic activity[1][2][3].
(1E,2E,4E)-1-[5-[(4-hydroxyphenyl)methyl]-2,4-dioxopyrrolidin-3-ylidene]-4,6-dimethylocta-2,4-dien-1-olate
7-(2,5-Dihydroxy-3,4,6-trimethylphenyl)-7-phenylhept-6-enoic acid
Ethyl (2S,3S)-3-[[(2S)-1-[[(2S)-1-hydroxypent-4-yn-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylate
7-Benzyl-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
N-hydroxy-N-[(E)-(4-pyridin-2-ylphenyl)methylideneamino]heptanediamide
N-hydroxy-N-[(E)-(4-pyridin-4-ylphenyl)methylideneamino]heptanediamide
N-hydroxy-N-[(E)-(4-pyridin-3-ylphenyl)methylideneamino]heptanediamide
1-(4-methoxyphenyl)-N-[2-(4-morpholinyl)ethyl]-4-pyrazolo[3,4-d]pyrimidinamine
N-[2-[4-(dimethylamino)phenyl]-4-oxo-1,2-dihydroquinazolin-3-yl]carbamic acid ethyl ester
1-(2,4-Diphenyl-2,3-dihydro-1,5-benzodiazepin-1-yl)propan-1-one
1-[(2R,3R)-1-[(2-fluorophenyl)methyl]-2-(hydroxymethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]ethanone
1-[(2S,3R)-1-[(2-fluorophenyl)methyl]-2-(hydroxymethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]ethanone
1-[(2S,3S)-1-[(2-fluorophenyl)methyl]-2-(hydroxymethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]ethanone
Tert-butyldifluorotris(trimethylsilyl)methylsilane
1-Pentamethyldisilanyloxy-4-pentamethyldisilanylbenzene
1-lauroyl-sn-glycerol 3-phosphate
A 1-acyl-sn-glycerol 3-phosphate having lauroyl (dodecanoyl) as the 1-O-acyl group.
JZP-430
JZP-430 is a potent, highly selective, irreversible inhibitor of α/β-hydrolase domain 6 (ABHD6) with an IC50 of 44 nM, exhibits ~230-fold selectivity over fatty acid amide hydrolase (FAAH) and lysosomal acid lipase (LAL)[1].
